端肺高血压:针对内科医生的专注审查
Mamta S Chhabria1, Leela Krishna Teja Boppana2, Gaurav Manek1
1Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic journal of medicine
|October 2, 2023
概括
港肺高血压 (PPH) 影响肝移植资格和患者的治疗结果. 目前正在进行研究,以了解其复杂的原因,并通过全面的患者评估来改善诊断.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 肺部医学 肺部医学
背景情况:
- 端口肺高血压 (PPH) 被定义为肺动脉高血压 (PAH) 在患有并存端口高血压的患者.
- PPH显著影响肝移植资格,并与预后不佳有关.
- 基本的PPH病原体尚未完全理解,是活跃的研究领域.
研究的目的:
- 总结一下目前对口肺高血压的理解.
- 突出PPH的诊断挑战和方法.
- 为了强调PPH在肝病管理中的临床意义.
主要方法:
- 现有关于端肺高血压的研究的文献综述.
- 对诊断标准和临床评估方法的分析.
- 讨论拟议的致病遗传机制.
主要成果:
- PPH呈现了一个复杂的临床场景,影响了移植候选人.
- 多种拟议的机制有助于PPH发展.
- 准确的诊断依赖于多方面的方法.
结论:
- 港肺高血压需要进行彻底的诊断评估.
- 了解PPH的发病性对于改善患者的治疗结果至关重要.
- 多学科评估是管理PPH患者的关键.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
207
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
207
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
249
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
249
Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191


